Alzheimer disease trials in France

In France 85 Also abroad 815

85 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer’s Disease Caused by a Genetic Mutation
Where
Bron, Lille Cedex, Paris Cedex 13, Rouen Cedex, Toulouse
Age
18 years and over
People
27 worldwide
Run by
Washington University School Of Medicine
See details and how to join2024-517187-36-01 · EU 2024-517187-36-01
Phase 2Taking people
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
Where
Bron, Lille Cedex, Montpellier Cedex 5, Paris, Toulouse
Age
50 years to 90 years
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07781657 · EU 2026-526158-14-00
Phase 2/3Taking people
ACP-204 in Adults With Alzheimer's Disease Psychosis
Where
Bron, Colmar Cedex, Dijon, Limoges, Paris, Paris Cedex 10, Rouen, Toulouse, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy, Villeurbanne
Age
55 years to 95 years
People
1,074 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673 · EU 2023-507325-42-00
No phaseTaking people
Identification of Diagnosis Biomarkers in the Tears of Alzheimer's Disease Patients: The COG-EYE Pilot Study
Where
Tours
Age
18 years and over
People
90
Run by
University Hospital, Tours
See details and how to joinNCT06661564
Phase 3Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Where
Bron, Colmar Cedex, Dijon, Limoges, Paris, Paris Cedex 10, Rouen, Toulouse, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy, Villeurbanne
Age
55 years to 95 years
People
752 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799 · EU 2023-507351-29-00
Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Lille Cedex, Limoges Cedex 1, Montpellier Cedex 5, Paris, Strasbourg, Toulouse Cedex 9, Villeurbanne
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
No phaseTaking people
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
Where
Paris
Age
18 years and over
People
450
Run by
Fondation Ophtalmologique Adolphe de Rothschild
See details and how to joinNCT04389437
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Nice, Toulouse, Tours
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Dijon, Montpellier Cedex 5, Nice, Reims Cedex, Rouen Cedex, Toulouse, Villeurbanne
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Nice, Reims Cedex, Rouen Cedex, Toulouse, Tours
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Lille Cedex, Limoges, Montpellier Cedex 5, Paris, Strasbourg, Toulouse Cedex 9, Villeurbanne
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Bordeaux, Bron, Lille Cedex, Marseille, Nancy, Paris, Rennes Cedex 9, Saint-Herblain, Strasbourg, Toulouse Cedex 9, Tours
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Strasbourg, Toulouse Cedex 9
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
No phaseTaking people
Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials
Where
Dijon
Age
18 years and over
People
74
Run by
Centre Hospitalier Universitaire Dijon
See details and how to joinNCT05888961
No phaseTaking people
Study of Repetitive Behaviors in Alzheimer's Disease
Where
Limoges
Age
18 years and over
People
103
Run by
Centre Hospitalier Esquirol
See details and how to joinNCT07732842
No phaseTaking people
ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness
Where
Huningue
Age
45 years and over
People
50,000
Run by
Firalis SA
See details and how to joinNCT07679906
No phaseTaking people
Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease
Where
Castres, Lavaur, Paris, Saint-Herblain, Toulouse, Villeurbanne
Age
55 years to 85 years
People
108
Run by
REGEnLIFE SAS
See details and how to joinNCT05926011
Phase 2/3Taking people
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Where
ORSAY, Paris Cedex 13
Age
40 years to 80 years
People
45
Run by
Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT04150198 · EU 2024-519995-20-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Where
Dijon, Reims, Rouen, Villeurbanne
Age
55 years to 90 years
People
410 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363
Phase 2Enrolling by invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Where
Strasbourg, Toulouse
Age
55 years to 91 years
People
210 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00
No phaseTaking people
Effects of Musical Intervention by a Therapist (IMT) on Falling Asleep and Behavioral Regulation in a Secure Care Unit (SCU)
Where
Saint-Etienne
Age
60 years and over
People
48
Run by
Centre Hospitalier Universitaire de Saint Etienne
See details and how to joinNCT07465783
No phaseTaking people
Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease
Where
Grenoble, Saint-Etienne, Villeurbanne
Age
60 years and over
People
80
Run by
Centre Hospitalier Universitaire de Saint Etienne
See details and how to joinNCT07632755
Phase 2/3Taking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Bron, Lille, Paris, Rouen, Toulouse
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
Phase 2/3Taking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Bron, Lille, Paris, Rouen, Toulouse
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498
Phase 2Taking people
Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
Where
Toulouse
Age
60 years to 100 years
People
100
Run by
University Hospital, Toulouse
See details and how to joinNCT07007208 · EU 2023-507668-38-00